This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
|Videos|May 6, 2022
Making obstetrics and gynecology a more diverse and equitable environment
Author(s)Morgan Ebert
In this EdTalk, presented at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting, Lisa Foglia, MD; Andrea L. Braden, MD; and Catherine Cansino, MD, MPH, discuss strategies for improving diversity and equity within obstetrics and gynecology.
Advertisement
Advertisement
Related to this article
This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
FAQ: Who is a candidate for testosterone therapy in women?
3
FAQ: What does the evidence show about testosterone in women?
4
Q&A: Kanchi Chadha, MD, FACOG, MSCP, on FDA boxed warning removals
5